Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Justin N. Malinou, MD, Hanan Alkhaldi, MD, Saurabh Dahiya, MD, Olga Goloubeva, PhD MSc, Ali Bukhari, MD, Forat Lutfi, MD, Gabriela Sanchez-Petitto, MD, Santanu Samanta, MD, Aaron P. Rapoport, MD, Nancy M. Hardy, MD, Nicolette Minas, MS, Kathleen Ruehle, RN, Natalie Gahres, RN, Linda Ridge, RN, BA, CCTC, Pranshu Mohindra, MD, Jason Molitoris, MD, Jean A. Yared, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142140

Published: 2020

Journal Articles

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Gabriela Sanchez-Petitto, MD, Olga Goloubeva, PhD MSc, James Childress, MD, Tahreem Iqbal, MD, Jack Masur, MD, Max An, BS, Safwan Muhammad, MD, Justin Lawson, PharmD BCOP, Jasmin Sahbaz, MD, Brian Barr, MD, Vu H. Duong, MD, Jennie Y. Law, MD, Ashkan Emadi, MD, PhD, Maria R. Baer, MD, Sandrine Niyongere, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138534

Published: 2020

Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD

Blood (2017) 130 (Supplement 1): 1243.

https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243

Published: 2017

Journal Articles

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Cameron Dell, BS, Olga Goloubeva, PhD MSc, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Nancy M. Hardy, MD, Jean Yared, MD, Ning Ma, CRNP, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 2177.

https://doi.org/10.1182/blood.V130.Suppl_1.2177.2177

Published: 2017

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Shahbaz A. Malik, MD, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Z Badros, MD, Nancy M. Hardy, MD, Mehmet H. Kocoglu, MD, Alison Duffy, Kathleen Ruehle, Jennifer Nishioka, Olga Goloubeva, PhD, Jean Yared, MD

Blood (2015) 126 (23): 5507.

https://doi.org/10.1182/blood.V126.23.5507.5507

Published: 2015

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.

Yin Wu, MD, Olga Goloubeva, PhD, Kathleen Ruehle, Saul Yanovich, MD, Aaron P. Rapoport, MD, Gorgun Akpek, MD, MS, Ashraf Z. Badros, MD

Blood (2008) 112 (11): 3327.

https://doi.org/10.1182/blood.V112.11.3327.3327

Published: 2008

Journal Articles

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Ashraf Badros, MD, Jay S. Dalal, MD, Olga Goloubeva, PhD, Jenni Thompson, Phrm.D., Kelly Yager, RN, Can Ilyas, MD, Aaron P. Rapoport, MD, Robert G. Fenton, MD, PhD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 3534.

https://doi.org/10.1182/blood.V108.11.3534.3534

Published: 2006

Journal Articles

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

Ashraf Z. Badros, MD, Olga Goloubeva, PhD, Saranya Chumsri, MD, Kathleen Ruehle, RN, Yi Ning, PhD, Joann Meekins, PhD, Liliana Guedez, PhD, Aaron P. Rapoport, MD, Barry Meisenberg, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5024.

https://doi.org/10.1182/blood.V108.11.5024.5024

Published: 2006

Journal Articles

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Ashraf Badros, MD, Olga Goloubeva, PhD, Dianna Weikel, DDS, Aaron P. Rapoport, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Timothy Meiller, DDS, PhD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5026.

https://doi.org/10.1182/blood.V108.11.5026.5026

Published: 2006

Journal Articles

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Ashrof Z. Badros, MD, Olga Goloubeva, PhD, Bashi Ratterree, RN, Sabrina Natt, RN, Aaron Rapoport, MD, Javier Bolaños-Meade, MD, Ben Zhang, PhD, Jerry Zeldis, MD, PhD, Stanley Frankel, MD, Barry Meisenberg, MD, James Zwiebel, MD, J. Flaws, PhD, D. Tomic, PhD, Robert Fenton, MD, PhD

Blood (2004) 104 (11): 2400.

https://doi.org/10.1182/blood.V104.11.2400.2400

Published: 2004

NARROW

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only